Fexofenadine Hydrochloride interactions
Checked as Fexofenadine in this data source.
Full monograph for Fexofenadine HydrochlorideCheck it against another medicine
Medicines
582 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Aluminium Hydroxide + Magnesium Hydroxide | Moderate | Absorption | INTERVAL: The concomitant administration of aluminum or magnesium-containing antacids with fexofenadine reduces its peak serum concentrations (Cmax) by 43% and…2 documented mechanisms | 3 sources — open the full entry |
| Aluminium Hydroxide + Magnesium Hydroxide + Simethicone | Moderate | Absorption | INTERVAL: The concomitant administration of aluminum or magnesium-containing antacids with fexofenadine reduces its peak serum concentrations (Cmax) by 43% and…2 documented mechanisms | 3 sources — open the full entry |
| Apalutamide | Moderate | Absorption · Metabolism | Coadministration with apalutamide may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4, 2C9, 2C19, breast… | 5 sources — open the full entry |
| Asciminib | Moderate | Others | Coadministration with asciminib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. In vitro… | 1 sources — open the full entry |
| Bempedoic acid | Moderate | Metabolism | Coadministration with bempedoic acid may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of the uptake… | 3 sources — open the full entry |
| Bempedoic acid + Ezetimibe | Moderate | Metabolism · Unknown | Coadministration with bempedoic acid may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of the uptake…2 documented mechanisms | 3 sources — open the full entry |
| Brigatinib | Moderate | Excretion | Coadministration with brigatinib may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of P-glycoprotein (P-gp)… | 4 sources — open the full entry |
| Cabozantinib | Moderate | Others | Based on in vitro inhibition data, coadministration with cabozantinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein… | 2 sources — open the full entry |
| Calcium acetate + Magnesium carbonate | Moderate | Absorption | INTERVAL: The concomitant administration of aluminum or magnesium-containing antacids with fexofenadine reduces its peak serum concentrations (Cmax) by 43% and… | 3 sources — open the full entry |
| Capmatinib Hydrochloride | Moderate | Absorption | Coadministration with capmatinib may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of P-glycoprotein (P-gp)… | 1 sources — open the full entry |
| Daclatasvir | Moderate | Excretion | Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed… | 2 sources — open the full entry |
| Daclatasvir + Sofosbuvir | Moderate | Excretion | Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed… | 2 sources — open the full entry |
| Darolutamide | Moderate | Metabolism | Coadministration with darolutamide may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptides (OATP)… | 4 sources — open the full entry |
| Elacestrant | Moderate | Absorption | Coadministration with elacestrant may increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp) and/or breast cancer resistance… | 1 sources — open the full entry |
| Elagolix Sodium | Moderate | Others | Coadministration with elagolix may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed… | 2 sources — open the full entry |
| Eltrombopag Olamine | Moderate | Metabolism | Coadministration with eltrombopag may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1… | 7 sources — open the full entry |
| Eluxadoline | Moderate | Others | Coadministration with eluxadoline may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1… | 11 sources — open the full entry |
| Enasidenib | Moderate | Distribution | Based on in vitro data, coadministration with enasidenib may increase the plasma concentrations of drugs that are substrates of the transporters, organic anion… | 3 sources — open the full entry |
| Enzalutamide | Moderate | Metabolism | Coadministration with enzalutamide may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, 2C9, 2C19, and/or P-glycoprotein (P-gp)… | 4 sources — open the full entry |
| Erdafitinib | Moderate | Distribution | Coadministration with erdafitinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter… | 1 sources — open the full entry |
| Flibanserin | Moderate | Others | Coadministration with flibanserin may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter. | 2 sources — open the full entry |
| Gilteritinib Fumarate | Moderate | Absorption | Coadministration with gilteritinib may increase the plasma concentrations and the risk of adverse effects of orally administered drugs that are substrates of… | 3 sources — open the full entry |
| Ibrutinib | Moderate | Absorption | Coadministration with ibrutinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter. In vitro… | 21 sources — open the full entry |
| Istradefylline | Moderate | Others | Coadministration with istradefylline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed… | 2 sources — open the full entry |
| Lasmiditan Hemisuccinate | Moderate | Distribution | Coadministration with lasmiditan may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer… | 1 sources — open the full entry |
| Ledipasvir + Sofosbuvir | Moderate | Absorption · Metabolism | Coadministration with ledipasvir may increase the plasma concentrations of orally administered drugs that are substrates of the P-glycoprotein (P-gp) and/or…2 documented mechanisms | 2 sources — open the full entry |
| Lorlatinib | Moderate | Excretion | Coadministration of lorlatinib with drugs that are P-glycoprotein (P-gp) substrates may decrease the plasma concentration and pharmacologic effect of the P-gp… | 4 sources — open the full entry |
| Magaldrate | Moderate | Absorption | INTERVAL: The concomitant administration of aluminum or magnesium-containing antacids with fexofenadine reduces its peak serum concentrations (Cmax) by 43% and… | 3 sources — open the full entry |
| Magaldrate + Simethicone | Moderate | Absorption | INTERVAL: The concomitant administration of aluminum or magnesium-containing antacids with fexofenadine reduces its peak serum concentrations (Cmax) by 43% and… | 3 sources — open the full entry |
| Magnesium Hydroxide | Moderate | Absorption | INTERVAL: The concomitant administration of aluminum or magnesium-containing antacids with fexofenadine reduces its peak serum concentrations (Cmax) by 43% and… | 3 sources — open the full entry |
| Magnesium Hydroxide + Liquid Paraffin | Moderate | Absorption | INTERVAL: The concomitant administration of aluminum or magnesium-containing antacids with fexofenadine reduces its peak serum concentrations (Cmax) by 43% and… | 3 sources — open the full entry |
| Neratinib Maleate | Moderate | Others | Coadministration with neratinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed… | 4 sources — open the full entry |
| Nilotinib | Moderate | Metabolism | Based on in vitro inhibition data, coadministration with nilotinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein… | 6 sources — open the full entry |
| Ponatinib Hydrochloride | Moderate | Others | Based on in vitro inhibition data, coadministration with ponatinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein… | 2 sources — open the full entry |
| Relugolix | Moderate | Absorption | Concomitant use with relugolix may lead to increased plasma concentrations of substrates of the intestinal efflux transporter, P-glycoprotein (P-gp). According… | 3 sources — open the full entry |
| Relugolix + Estradiol + Norethindrone | Moderate | Absorption · Unknown | Concomitant use with relugolix may lead to increased plasma concentrations of substrates of the intestinal efflux transporter, P-glycoprotein (P-gp). According…3 documented mechanisms | 3 sources — open the full entry |
| Rifampicin | Moderate | Absorption | The coadministration with rifampin may decrease the oral bioavailability of fexofenadine. The mechanism is rifampin induction of intestinal P-glycoprotein… | 3 sources — open the full entry |
| Rifampicin + Isoniazid | Moderate | Absorption · Unknown | The coadministration with rifampin may decrease the oral bioavailability of fexofenadine. The mechanism is rifampin induction of intestinal P-glycoprotein…2 documented mechanisms | 3 sources — open the full entry |
| Rifampicin + Isoniazid + Pyrazinamide + Ethambutol | Moderate | Absorption · Unknown | The coadministration with rifampin may decrease the oral bioavailability of fexofenadine. The mechanism is rifampin induction of intestinal P-glycoprotein…2 documented mechanisms | 3 sources — open the full entry |
| Risdiplam | Moderate | Excretion | Coadministration with risdiplam may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of multidrug and toxin… | 3 sources — open the full entry |
| Selpercatinib | Moderate | Absorption · Excretion · Metabolism | Coadministration with selpercatinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed… | 2 sources — open the full entry |
| Sorafenib Tosylate | Moderate | Others | Based on in vitro inhibition data, coadministration with sorafenib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein… | 3 sources — open the full entry |
| Sotorasib | Moderate | Absorption | Coadministration with sotorasib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer… | 4 sources — open the full entry |
| Tolvaptan | Moderate | Distribution | Coadministration with tolvaptan may increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp). The proposed mechanism is… | 5 sources — open the full entry |
| Tucatinib | Moderate | Absorption | Coadministration with tucatinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The mechanism… | 1 sources — open the full entry |
| Ulipristal Acetate [For emergency contraception] | Moderate | Others | Based on in vitro inhibition data, coadministration with ulipristal may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein… | 1 sources — open the full entry |
| Ulipristal Acetate [For uterine fibroids] | Moderate | Others | Based on in vitro inhibition data, coadministration with ulipristal may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein… | 1 sources — open the full entry |
| Venetoclax | Moderate | Others | Coadministration with venetoclax may increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp). The proposed mechanism is… | 4 sources — open the full entry |
| Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine | Minor | Absorption · Unknown | Coadministration with ketoconazole has been shown to significantly increase the oral bioavailability of fexofenadine. The proposed mechanism is ketoconazole…2 documented mechanisms | 4 sources — open the full entry |
| Betamethasone + Clotrimazole | Minor | Absorption | Coadministration with ketoconazole has been shown to significantly increase the oral bioavailability of fexofenadine. The proposed mechanism is ketoconazole… | 4 sources — open the full entry |
Food & lifestyle
grapefruit juice
ModerateAbsorption
Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine. The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.
What to do: To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water. In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.
2 sources
- Bailey DG, Dresser GK, Munoz C, Freemar DJ, Kim RB "Reduction of fexofenadine bioavailability by fruit juices." Clin Pharmacol Ther 69 (2001): PI-82
- Dresser GK, Bailey DG, Leake BF, et al. "Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine." Clin Pharmacol Ther 71 (2002): 11-20
orange juice
ModerateAbsorption
Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine. The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.
What to do: To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water. In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.
2 sources
- Bailey DG, Dresser GK, Munoz C, Freemar DJ, Kim RB "Reduction of fexofenadine bioavailability by fruit juices." Clin Pharmacol Ther 69 (2001): PI-82
- Dresser GK, Bailey DG, Leake BF, et al. "Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine." Clin Pharmacol Ther 71 (2002): 11-20
Conditions
Conditions in which Fexofenadine Hydrochloride needs care, as documented in this source.
Kidney Diseases
ModerateFexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance. Care should be taken in dose selection and it may be useful to monitor renal function.
2 sources
- "Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel (2001):
- Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998): 612-21
Therapeutic duplication
Drug classes that overlap with Fexofenadine Hydrochloride, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
antihistamines
The recommended maximum number of medicines in the 'antihistamines' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antihistamines' category.
Example product in the source data (US market): First mouthwash blm